Key clinical point: Even though disease-free survival (DFS) outcomes were comparable in patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC), the degree of nodal involvement affected prognostic outcomes in both these populations.
Major finding: In patients with ILC vs IDC, DFS was similar in the overall population ( P = .743), but it was significantly worse (pN2/pN3; adjusted hazard ratio [aHR] 1.40; P = .033) and better (pN0/pN1; aHR 0.60; P = .005) in patients with extensive and limited nodal involvement, respectively.
Study details: Findings are from a pooled analysis of three phase 3 trials, SUCCESS A, B, and C, which included 7236 intermediate-to-high risk patients with IDC (n = 6284) or ILC (n = 952) and who received adjuvant chemotherapy.
Disclosures: The SUCCESS trials were supported by AstraZeneca, Sanofi-Aventis, and other sources. Two authors declared receiving honoraria from various sources unrelated to this work. Other authors declared no conflicts of interest.
Source: Dayan D et al. Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: Results from the SUCCESS trials. Breast Cancer Res. 2023;25:153 (Dec 14). doi: 10.1186/s13058-023-01750-0